Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids Jan 12, 2023 07:00AM
JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020 Apr 9, 2020 10:10AM
Matinas BioPharma to Present at the 9th Annual LD Micro Invitational Jun 3, 2019 08:05AM
Matinas BioPharma (MTNB) Reports Publication of MAT2203 Preclinical Cryptococcal Meningitis Data May 28, 2019 08:06AM
Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio May 28, 2019 08:00AM
View Older Stories

May 21, 2019 08:00AM Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019
May 15, 2019 07:00AM Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
May 2, 2019 08:35AM Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019
Feb 25, 2019 08:05AM Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Jan 10, 2019 08:00AM Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform
Jan 3, 2019 08:21AM Matinas BioPharma (MTNB) Names Keith Kucinski CFO
Jan 3, 2019 08:20AM Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer
Dec 20, 2018 08:35AM Matinas BioPharma to Present at Biotech Showcase 2019
Dec 19, 2018 08:35AM Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board
Dec 6, 2018 09:00AM Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001
Nov 12, 2018 07:00AM Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 18, 2018 08:03AM Matinas BioPharma (MTNB) Announces Issuance of U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001
Oct 18, 2018 08:00AM Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033
Oct 16, 2018 08:00AM Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference
Oct 15, 2018 08:01AM Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
Sep 25, 2018 08:00AM Matinas BioPharma to Present at the MicroCap Conference
Sep 6, 2018 08:17AM Matinas BioPharma (MTNB) Announces Patrick G. LePore to Board
Sep 6, 2018 08:01AM Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors
Sep 5, 2018 08:00AM Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Aug 16, 2018 08:00AM Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop
Aug 10, 2018 08:15AM Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Jul 9, 2018 09:15AM NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology
Jun 12, 2018 08:00AM Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host
Jun 6, 2018 07:35AM Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform
May 10, 2018 07:05AM Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 7, 2018 08:05AM Matinas BioPharma to Host Quarterly Update Conference Call
May 1, 2018 08:05AM Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference
Apr 19, 2018 08:05AM Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease
Mar 26, 2018 04:45PM Matinas BioPharma Reports 2017 Financial Results
Mar 16, 2018 05:00PM Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update
Mar 15, 2018 08:00AM Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference
Mar 12, 2018 08:05AM Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast
Jan 8, 2018 07:21AM Matinas BioPharma (MTNB) Announces Achievement of Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203
Jan 8, 2018 07:01AM Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
Dec 14, 2017 07:14AM Matinas BioPharma (MTNB) Appoints Matthew A. Wikler to Board
Dec 14, 2017 07:01AM Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors
Nov 15, 2017 07:35AM Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Oct 11, 2017 08:05AM Matinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference
Sep 19, 2017 09:20AM Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 12, 2017 07:35AM Matinas BioPharma (MTNB) to Review Strategic Options for MAT9001
Sep 12, 2017 07:30AM Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001
Aug 8, 2017 06:05AM Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501
Aug 3, 2017 08:05AM Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference
Aug 1, 2017 08:30AM Matinas BioPharma to Host Quarterly Update Conference Call
Jun 26, 2017 06:09AM Matinas BioPharma (MTNB) Presents Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
Jun 26, 2017 06:05AM Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis
Jun 5, 2017 06:05AM Matinas BioPharma (MTNB) Reports Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203
Jun 3, 2017 04:00PM Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
Jun 2, 2017 04:01PM Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
Jun 1, 2017 07:05AM Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference
View Older Stories